Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
NCT07678775
·
clinicaltrials.gov ↗
PHASE3
Phase
ACTIVE_NOT_RECRUITING
Status
107
Enrollment
INDUSTRY
Sponsor class
Conditions
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Interventions
DRUG:
BBP-418 (ribitol)
Sponsor
ML Bio Solutions, Inc.